Enhancing the study on antithrombotic therapy after stroke in AF patients.
作者信息
Wang Shen
机构信息
School of Public Health, China Medical University, 77 Puhe Road, Shenbei New District, Shenyang, Liaoning Province 110122, China.
School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, Northern Ireland BT9 7BL, UK.
出版信息
Europace. 2024 Jun 3;26(6). doi: 10.1093/europace/euae147.
Abstract
摘要
相似文献
1
Enhancing the study on antithrombotic therapy after stroke in AF patients.加强对房颤患者卒中后抗栓治疗的研究。
Europace. 2024 Jun 3;26(6). doi: 10.1093/europace/euae147.
2
Atrial fibrillation: stroke prevention in older adults.心房颤动：老年人的卒中预防。
Clin Geriatr Med. 2012 Nov;28(4):617-34. doi: 10.1016/j.cger.2012.08.003.
3
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.心房颤动的抗血栓治疗：抗血栓治疗和血栓预防，第 9 版：美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e531S-e575S. doi: 10.1378/chest.11-2304.
4
Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk.老年护理机构中房颤患者抗栓治疗的居家药物管理评估：卒中与出血风险评估
J Clin Pharm Ther. 2016 Jun;41(3):279-84. doi: 10.1111/jcpt.12385. Epub 2016 Apr 7.
5
[Your patient needs antithrombotic drugs, 7. Averting the risk of stroke: with whom and how?].[您的患者需要抗血栓药物，7. 预防中风风险：与谁一起以及如何预防？]
MMW Fortschr Med. 2013 Jul 25;155(13):24. doi: 10.1007/s15006-013-1123-6.
6
Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan.日本房颤患者卒中预防的抗栓治疗。
Expert Opin Pharmacother. 2020 Dec;21(17):2115-2124. doi: 10.1080/14656566.2020.1799976. Epub 2020 Aug 4.
7
[Anticoagulation after stroke: what works, what does not?].[中风后的抗凝治疗：哪些有效，哪些无效？]
MMW Fortschr Med. 2015 Nov 12;157 Spec No 2:22. doi: 10.1007/s15006-015-3519-y.
8
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.出血是一种必要的恶吗？用于心房颤动卒中预防的抗栓药物治疗的内在风险。
Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1029-49. doi: 10.1586/14779072.2013.815423.
9
Anticoagulation strategies in atrial fibrillation.心房颤动的抗凝策略。
Rev Cardiovasc Med. 2012;13(1):e1-13. doi: 10.3909/ricm0616.
10
Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.欧洲心脏病学会指南指导下的抗栓治疗改善了高危房颤患者的预后：来自 EORP-AF 一般试点登记处的报告。
Europace. 2015 Dec;17(12):1777-86. doi: 10.1093/europace/euv269. Epub 2015 Aug 30.
本文引用的文献
1
The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The "Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis" Registry.临床实践中双途径抑制的净临床结局：“利伐沙班联合乙酰水杨酸：动脉粥样硬化患者的治疗模式与结局”登记研究
J Clin Med. 2024 Mar 28;13(7):1956. doi: 10.3390/jcm13071956.
2
Association between antithrombotic therapy after stroke in patients with atrial fibrillation and the risk of net clinical outcome: an observational cohort study.房颤患者卒中后抗栓治疗与净临床结局风险的关联：一项观察性队列研究。
Europace. 2024 Feb 1;26(2). doi: 10.1093/europace/euae033.
3
A systematic assessment of preclinical multilaboratory studies and a comparison to single laboratory studies.系统评估临床前多实验室研究并与单实验室研究进行比较。
Elife. 2023 Mar 9;12:e76300. doi: 10.7554/eLife.76300.
4
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups.依度沙班与华法林用于伴有心房颤动的高危患者：高危亚组的综合分析。
Am Heart J. 2022 May;247:24-32. doi: 10.1016/j.ahj.2021.12.017. Epub 2022 Jan 3.
5
A comparison of natural language processing to ICD-10 codes for identification and characterization of pulmonary embolism.用于识别和表征肺栓塞的自然语言处理与国际疾病分类第10版（ICD - 10）编码的比较。
Thromb Res. 2021 Jul;203:190-195. doi: 10.1016/j.thromres.2021.04.020. Epub 2021 May 6.
6
Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation.与非瓣膜性心房颤动患者接受直接口服抗凝剂治疗的安全性和疗效相关的临床因素。
Sci Rep. 2020 Nov 19;10(1):20144. doi: 10.1038/s41598-020-77174-z.
7
A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.一项源自 ENGAGE AF-TIMI 48 随机临床试验的新型房颤净临床结局风险预测评分。
Eur Heart J. 2017 Mar 21;38(12):888-896. doi: 10.1093/eurheartj/ehw565.
Zotero 插件